Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced the completion of Phase II clinical research for its innovative traditional Chinese medicine, Zhilong Tongluo Pian, which shows promising results for treating ischemic stroke recovery [1] Group 1: Clinical Research Findings - The drug is indicated for conditions such as post-stroke recovery, including symptoms like hemiplegia, speech difficulties, and fatigue [1] - Safety results indicate no statistically significant differences in severe adverse events or reactions among groups, with all severe events related to acute stroke recurrence and no fatalities reported [1] - Zhilong Tongluo Pian demonstrated effectiveness in improving the Rankin scale for disability, enhancing neurological function, and increasing daily living capabilities [1] Group 2: Efficacy and Recommendations - The drug is effective for symptoms related to blood stasis and Qi deficiency, including upper limb paralysis and fatigue, with a trend towards efficacy in lower limb paralysis and speech difficulties [1] - Both low-dose and high-dose groups showed comparable efficacy, with a recommendation to continue Phase III clinical research for the low-dose group [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-082 湖南方盛制药股份有限公司 关于蛭龙通络片获得II期临床试验总结报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 9 月 22 日，湖南方盛制药股份有限公司（以下简称 "公司"）研发的中药创新药蛭龙通络片取得了 II 期临床研究报 告。为保证所有投资者获取信息的公平、准确、完整，并及时了 解公司经营动态，根据上海证券交易所《上市公司行业信息披露 指引第六号——医药制造》相关规定，公司现将有关内容公告如 下： 一、基本情况 药品名称：蛭龙通络片 剂型：片剂 研究类型：II 期临床试验 临床批件号：2011L01961 获得临床批复时间：2011 年 11 月 5 日 公司于 2013 年 6 月受让北京同御康泰科技有限公司的蛭龙 通络片临床试验批件、处方、生产工艺、质量标准等相关原始研 究资料和技术。2014 年 5 月 20 日， ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced the completion of Phase II clinical research for its innovative traditional Chinese medicine, Zhilong Tongluo Pian, which shows promising results for treating ischemic stroke recovery [1] Group 1: Clinical Research Findings - The drug is indicated for conditions such as post-stroke recovery, including symptoms like hemiplegia, speech difficulties, and fatigue [1] - Safety results indicate no statistically significant differences in severe adverse events or reactions among groups, with all severe events related to acute stroke recurrence and no fatalities reported [1] - Zhilong Tongluo Pian demonstrated effectiveness in improving the Rankin scale for disability, enhancing neurological function, and increasing daily living capabilities [1] Group 2: Efficacy and Recommendations - The drug is effective for symptoms related to blood stasis and Qi deficiency, including upper limb paralysis and speech issues, with a trend towards efficacy in lower limb paralysis and other symptoms [1] - Both low-dose and high-dose groups showed comparable efficacy, with a recommendation to continue Phase III clinical research for the low-dose group [1]

Core Viewpoint - Fangsheng Pharmaceutical announced that its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, has obtained the Phase II clinical research report, demonstrating significant efficacy in treating recovery from cerebral infarction (ischemic stroke) with good safety profile [1] Company Summary - Zhilong Tongluo Tablets are currently the company's exclusive product, with no other enterprises having obtained production approval for this product [1] - The clinical trial results indicate that both high-dose and low-dose groups show comparable efficacy [1] Market Summary - The sales revenue for traditional Chinese medicines treating cerebral infarction, such as Naoxintong Capsules and Tongxinluo Capsules, is projected to be 2.927 billion yuan and 2.273 billion yuan respectively in 2024 [1]

Market Overview - The Shanghai Composite Index closed at 3781.61 points, below the five-day moving average, with a decline of 1.23% [1] - The total trading volume of A-shares reached 171.35 billion yuan [1] Stocks Performance - A total of 119 A-shares broke through the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Chuangyuan Xinke (创远信科) with a deviation rate of 11.34% and a daily increase of 20.09% [1] - Teruid (特锐德) with a deviation rate of 10.64% and a daily increase of 13.85% [1] - Niutai Ge (纽泰格) with a deviation rate of 7.97% and a daily increase of 9.93% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Xinghua New Materials (星华新材) and Haixing Power (海兴电力) [1] - Other stocks with notable performance include: - Ningbo Haiyun (宁波海运) with a daily increase of 9.95% and a deviation rate of 7.96% [1] - Xusheng Group (旭升集团) with a daily increase of 10.03% and a deviation rate of 7.83% [1]

9月23日，方盛制药盘中上涨2.09%，截至10:44，报11.25元/股，成交1.09亿元，换手率2.24%，总市值 49.40亿元。 截至6月30日，方盛制药股东户数3.31万，较上期增加0.37%；人均流通股13245股，较上期减少0.36%。 2025年1月-6月，方盛制药实现营业收入8.34亿元，同比减少8.35%；归母净利润1.69亿元，同比增长 23.67%。 分红方面，方盛制药A股上市后累计派现6.89亿元。近三年，累计派现4.84亿元。 机构持仓方面，截止2025年6月30日，方盛制药十大流通股东中，工银医疗保健股票（000831）位居第 三大流通股东，持股539.97万股，持股数量较上期不变。融通健康产业灵活配置混合A/B（000727）位 居第四大流通股东，持股500.00万股，相比上期增加50.00万股。大成价值增长混合A（090001）位居第 五大流通股东，持股460.57万股，持股数量较上期不变。易方达医疗保健行业混合A（110023）、安信 医药健康股票A（010709）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流入196.72万元，特大单买入558.9 ...

Core Viewpoint - Fangsheng Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.09% on September 19, 2023, reflecting a total market value of 4.742 billion yuan and a year-to-date increase of 7.89% [1] Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported operating revenue of 834 million yuan, a year-on-year decrease of 8.35%, while net profit attributable to shareholders increased by 23.67% to 169 million yuan [2] - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 484 million yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2] - The top three circulating shareholders include Industrial Bank Medical Care Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, which increased its holdings by 500,000 shares to 5 million [3]

Core Viewpoint - Fangsheng Pharmaceutical's stock has shown mixed performance in recent trading, with a year-to-date increase of 13.69% but a recent decline over the past 20 days of 9.11% [2] Group 1: Stock Performance - As of September 18, Fangsheng Pharmaceutical's stock price rose by 2.25% to 11.38 CNY per share, with a trading volume of 1.29 billion CNY and a turnover rate of 2.64%, resulting in a total market capitalization of 4.997 billion CNY [1] - The stock has increased by 2.61% over the last five trading days and by 18.42% over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported operating revenue of 834 million CNY, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million CNY [2] - The company has distributed a total of 689 million CNY in dividends since its A-share listing, with 484 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Fangsheng Pharmaceutical was 33,100, an increase of 0.37% from the previous period, with an average of 13,245 circulating shares per shareholder, a decrease of 0.36% [2] - The top three circulating shareholders include Industrial Bank Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, which increased its holdings by 500,000 shares to 5 million [3]

证券代码：603998 证券简称：方盛制药 公告编号：2025-080 湖南方盛制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每股分配比例 A股每股现金红利0.15元 一、通过分配方案的股东会届次和日期 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交 易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者 可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分 公司保管，待办理指定交易后再进行派发。 本次利润分配方案经公司2025年5月20日的2024年年度股东大会审议通过，授权董事会办理中期利润分 配相关事宜，并经公司2025年8月27日召开第六届董事会第三次会议审议通过。 二、分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上 ...

证券日报网讯 9月11日晚间，方盛制药发布公告称，2025年半年度利润分配方案为A股每股现金红利 0.15元（含税），股权登记日为2025年9月17日，除权（息）日及现金红利发放日均为2025年9月18日。 （文章来源：证券日报） ...